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Diabetes mellitus (DM) is a kind of chronic and metabolic disease, which can cause
a number of diseases and severe complications. Network pharmacology approach is
introduced to study DM, which can combine the drugs, target proteins and disease and
form drug-target-disease networks. Network pharmacology has been widely used in the
studies of the bioactive compounds and action mechanisms of natural products for the
treatment of DM due to the multi-components, multi-targets, and lower side effects. This
review provides a balanced and comprehensive summary on network pharmacology
from current studies, highlighting different bioactive constituents, related databases
and applications in the investigations on the treatment of DM especially type 2. The
mechanisms related to type 2 DM, including α-amylase and α-glucosidase inhibitory,
targeting β cell dysfunction, AMPK signal pathway and PI3K/Akt signal pathway are
summarized and critiqued. It suggests that the network pharmacology approach cannot
only provide a new research paradigm for natural products, but also improve the current
antidiabetic drug discovery strategies. Furthermore, we put forward the perspectives on
the reasonable applications of network pharmacology for the therapy of DM and related
drug discovery.
Keywords: network pharmacology, diabetes mellitus, natural products, database, mechanism
INTRODUCTION
Diabetes mellitus (DM) has drawn much attention of researchers due to its increasing mortality
and complex complications. According to the International Diabetes Federation, DM has become
a major threat to the health and the third biggest killer after cardiovascular diseases and cancer1.
Now DM has terrible influences on both high- and low-income countries, with bearing the majority
of the burden in low-income countries. According to the latest statistics of WHO, DM directly
caused 1.5 million deaths in 2012. There were approximately 422 million (1 in every 11 people)
diabetics worldwide in 2014, which was 14-fold more than those in 19802. And the cases will reach
600 million by 2030 based on the developing trend (Kokil et al., 2015).
1http://www.diabetesatlas.org
2http://www.who.int/en/
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Diabetes mellitus is a group of chronic and metabolic diseases,
in which there are high blood glucose levels over a long period. It
is caused by either the body can’t produce enough insulin or the
body can’t effectively respond to the produced insulin. Based on
different pathogenesis, DM can be categorized into three types.
Type 1 diabetes mellitus (T1DM), namely insulin-dependent
DM or childhood-onset diabetes, is caused by insulin deficiency,
which is related to dysfunction β cells (Enk and Mandelboim,
2014). Type 2 diabetes mellitus (T2DM), namely non-insulin-
dependent DM or adult-onset diabetes, is characterized by insulin
resistance (IR) and relatively insulin secretion reducing. There
is another type of the diabetes, gestational diabetes mellitus
(GDM), which is characterized by high blood glucose levels in
pregnant women without previously diagnosed diabetes (Keller
et al., 2008; Puri and Hebrok, 2012). According to clinical and
non-clinical studies, T2DM is the main category accounting for
about 90% of diabetes cases, which is also the focus of this review.
The risk factors for T2DM are relatively clear including age,
obesity, lifestyle, dietary patterns gene-environment interactions
and epigenomics, etc. (Herman and Zimmet, 2012; Karter et al.,
2013; Maruthur, 2013). It is reported that multiple genes are
involved in genetic susceptibility. The pathogenesis of the DM
diseases are closely related to the alterations in multiple signal
pathways such as JAK-STAT, AMPK, and PI3K (Richard and
Stephens, 2011; Samuel and Shulman, 2012). And the changes of
microbial environment might affect the DM pathogenesis (Wen
et al., 2008). Study of Qin showed that gut microbial dysbiosis
and pathogenic bacteria increasing were observed in patients
with T2DM (Qin et al., 2012). If left untreated, DM can cause
many complications, including kidneys damage, eyes damage,
heart disease, stroke, bone fracture risks, and function failure
(Jason et al., 2016). So many recent studies are focusing on the
anti-diabetic drugs discovery.
A series of medicines, including analogs, sulfonylureas,
thiazolidinedione, biguanides, α-glucosidase inhibitors, and
DDP-4 inhibitors, have been used as commercial products for
therapy of DM (Morral, 2003; Tian N. et al., 2013). However,
because of the “one target, one drug” mechanism, they might have
similar side effects, such as weight gain, cardiovascular disease,
glycopenia, and gastrointestinal effects (Shah and Mudaliar,
2010). Considering the long-term treatment, side effects and high
price of the current antidiabetic drugs, there is a huge demand for
effective, low-toxic or non-toxic and affordable drugs for DM.
Compared with the synthetic drugs, natural products have
played an important role in DM treatment. The treatment
benefits are attributed to multi-components and multi-targets
to produce combined or synergistic effects. With the rapid
development of novel technologies, increasing studies have
been focused on antidiabetic natural products. Nowadays,
multi-components and multi-targets therapies have been
proved to be more effective and less toxicity than traditional
single-target drugs (Espinoza-Fonseca, 2006). With the rapid
progress of bioinformatics, network pharmacology, integrating
network biology and pharmacology, is considered as a promising
approach toward more cost-effective drug development
(Khan and Khan, 2016). It can reveal the underlying complex
relationship between multi-components and multi-targets.
Moreover, network pharmacology provides a system-level
approach to understand the pathogenesis of diseases, and can
be used for lead discovery, target identification and indication
prediction, which coincides with the holistic and systematic
concepts in traditional Chinese medicine (TCM) theory
(Hopkins, 2008; Tang and Aittokallio, 2014). Compared with
conventional “one gene, one drug, one disease” mode, network
pharmacology focuses on “multi-targets, multi-components”
treatment to diseases. And signal network analysis is a highly
attractive tool to investigate complex relationships. What’s more,
based on network pharmacology, feasible “drug-target-disease”
network models can be established through high-throughput
screening and bioinformatics (Poornima et al., 2016). It was
reported that network pharmacology had various applications,
such as herbal ingredient target/disease gene prediction, network
balance regulation, elucidation of synergistic ingredient pairs
and active ingredient groups (Tao et al., 2013; Zhang X. et al.,
2014; Zintzaras et al., 2014). Thus, strategies based on network
including network pharmacology and network medicine are
increasingly developed and applied. And several databases
have been established to assist network pharmacology analysis
including PhIN (pharmacology interaction network database)
(Wang Z. et al., 2015), C2Maps (computational connectivity
maps) (Huang et al., 2012), databases on TCM (Li and Zhang,
2013), CVDHD (The cardiovascular disease herbal database)
(Gu et al., 2013b) and anticancer drugs database (Azmi et al.,
2010).
In drug discovery, combined multi-components and multi-
targets, natural products based on network pharmacology can
afford bright perspectives for treating DM in a systematic
manner. It is an efficient and time-saving method to find the
potential application in other therapeutic categories of drugs by
predicting their targets. Therefore, the network pharmacology
approach is developed to find effective drugs for the treatment
of DM and related metabolic disorders such as obesity and
metabolic syndrome. Based on network pharmacology, the
antidiabetic compounds were detected from Ge-Gen-Qin-Lian
decoction formula, and the mechanisms were elucidated (Li et al.,
2014). In the study of Zhang S. et al. (2014), the “drug-target-
pathway-disease” network of green tea was established. And
neurotrophin signal pathway, p53 signal pathway, and T2DM
pathway related to DM were screened by network pharmacology
(Zhang S. et al., 2014). It was reported that the network
pharmacology analysis was developed to illustrate the action
mechanism of Tangminling Pills for T2DM therapy (Gu et al.,
2011).
The aim of this review is to provide a summary of network
pharmacology studies on the bioactive compounds and action
mechanisms of natural products for the treatment of DM. The
recent progresses on the different active constituents, databases
and applications in the treatment of DM were highlighted.
The mechanisms related to T2DM, including α-amylase and
α-glucosidase inhibitory, targeting β cell dysfunction, AMPK
signal pathway, PI3K/Akt signal pathway and modulation of
gut microbiota were summarized. And the perspectives on their
reasonable applications for therapy of DM and related drug
discovery were put forward.
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NETWORK PHARMACOLOGY ON DM
Databases of Natural Products
Natural products have played significant roles in the leads
for drug discovery, which were involved in the development
of approximately 64% of all drugs (Newman and Cragg,
2012). Databases of natural products are important for
screening in drug discovery. Thus, several databases were
established to provide the related information of natural
products.
Super Natural II3 (Banerjee et al., 2015), containing about
326,000 molecules, was a freely available database to find
natural products with different incorporating search functions.
The database contained approximately 170,000 compounds and
provided the following information of the products, including
two-dimentional structures, the corresponding structural and
physicochemical properties, the predicted toxicity class and the
vendor information etc.
NAPRALERT (Loub et al., 1985) was a source database.
The database collected the information of natural products
by textual-numeric. About 105,000 organism names, 195,000
pharmacological results and 190,000 identified compounds were
collected. In addition, it provided a strategy to prophetically
identify the classification source of the most promising specific
biological activities.
Chemical Entities of Biological Interest (ChEBI)4 (And
et al., 2003) was also a freely available dictionary focused
on small chemical compounds of either natural products or
synthetic products. The database represented more than 12,
000 molecular entities, groups and classes. Some important
information was provided such as ChEBI ID, ChEBI names,
definition, structural diagrams, formula, synonyms, and registry
number.
DrugBank (Wishart et al., 2008) was a database enriched
drug data. The 2.0 version of DrugBank presented about 4,900
drug entries, which included about 1,467 FDA-approved drugs.
In addition, the database contained common links to nearly
all primary bioinformatics and biomedical databases (GenBank,
KEGG, PubChem, and PubMed).
Other databases related to natural products were also
developed, such as PubChem (Wang et al., 2009), UPND
(Universal Natural Products Database) (Gu et al., 2013a),
Dictionary of Natural Products (DNPs)5, CHDD (Qiao et al.,
2002), Herb BioMap database (China Copyright of Computer
Sofware, 2011SR076502), Chinese Natural Product Database
(CNPD) (Zheng et al., 2005), Traditional Chinese Medicines
Database (TCMD) (He et al., 2001) and ChemBank (Seiler et al.,
2008).
All the databases can be useful for the studies involving
virtual screening and the design of new compounds from
natural compounds. The information about structures and
physicochemical properties is useful and it can contribute to
future drug development.
3http://bioinformatics.charite.de/supernatural
4http://www.ebi.ac.uk/chebi/
5http://dnp.chemnetbase.com
Natural Products for DM Therapy
Natural products have played an important role in DM therapy
for a long history, especially in Asia, India and Africa. There were
massive studies focused on herbal medicines for the development
and discovery of antidiabetic medicine. Many kinds of extracts
and bioactive constituents were studied on the hypoglycemic
effects.
Extracts
Extracts from natural products have been widely prescribed for
diabetic treatment worldwide. Some of them were evaluated
scientifically and methodically in order to check for their
properties (Odhav et al., 2010). Various plant extracts were
traditionally used to DM treatment. In a long-term study,
Annona muricata aqueous extract was daily administrated to
diabetic rats for 28 days, the blood glucose levels and serum
creatinine were reduced, and the MDA, AST, ALT activity,
and nitrite levels LDL-cholesterol were also reduced (Florence
et al., 2014). Khanra et al. (2015) reported that Abroma augusta
L. (Malvaceae) leaf extract could be considered as a kind of
prophylactic agent against T2DM and its associated kidney
and cardiac toxicity (Khanra et al., 2015). Chicory seed extract
had the capacity to target hyperglycemia, hyperlipidemia, IR,
NAFLD (non-alcoholic fatty liver disease) and NASH (non-
alcoholic steatohepatitis) through modulating PPARα/SREBP-1
ratio (Ziamajidi et al., 2013). There were other extracts used
for the DM treatment, such as Hypericum perforatum extract
(Hasanein and Shahidi, 2011), grape seed and skin extract
(Oueslati et al., 2016), and flavonoid rich extract from Sophora
tonkinensis Gagnep (Huang et al., 2016). So the herbal extracts
can be used for the treatment of T2DM at systematic levels.
Polysaccharides
Polysaccharides are one of the main components of the natural
sources and they are composed of more than 10 monosaccharide
units linked together by glycosidic bonds. As the main bioactive
fractions of natural products, polysaccharides have attracted
much more attention during recent years (Zong et al., 2012). As
shown in Table 1, polysaccharides from natural products were
applied for the DM treatment during the period 2010–2016.
According to our previous study (2015), tea polysaccharides
(TPS) were found to increase the body weight and decrease
the blood glucose. It had higher potent glucose tolerance. And
some biochemical indices were ameliorated. The TC and LDL-c
contents were decreased and the TG and HDL-c contents
were restored nearly to the normal levels. Furthermore, via
upregulating the expressions of PI3K, p-Akt and GLUT4 target
proteins in PI3K/Akt signal pathway, TPS could play an effective
role in hypoglycemia. It was indicated that TPS might be a
promising candidate for T2DM treatment (Li et al., 2015).
A water soluble TPS enhanced insulin secretion simulated
by glucose through cAMP-PKA pathway by upregulating not
only the mRNA transcription but also the expression of PDX-
1 protein (Wang H. et al., 2015). Polysaccharides of corn
silk (POCS) were evaluated for its antidiabetic effects on
streptozotocin (STZ)-induced diabetic rats. The results showed
that POCS could not only significantly decrease blood glucose
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level, but also reduce total cholesterol (TC) and total triglyceride
(TG) (Zhao W. et al., 2012). Mulberry leaf polysaccharides
were reported to effectively improve the hepatic glucose
metabolism and IR to the normal levels. By inhibiting the
expression of protein–tyrosine phosphatase 1B, activating the
PI3K/AKT signal pathway and relieving oxidative stress, the
polysaccharides were proved to be a prophylactic agent for
T2DM (Ren et al., 2014). What’s more, polysaccharides from
Lachnum calyculiforme (Ye et al., 2011) and polysaccharides
from Cynomorium songaricum (Wang et al., 2010) exhibited
obvious hypoglycemic effects. The polysaccharides can be
applied in the treatment of DM by targeting different signal
pathways.
Polyphenols
Antidiabetic polyphenols extracted from natural products in
the period 2010–2016 were listed in Table 2. Polyphenols, the
secondary metabolites of plants, are mainly responsible for the
flavor and color of fruits and other plant products. They are
presented in fresh fruits and vegetables and found in various
natural beverages such as red wines, tea and cocoa (Quideau
et al., 2011). Solayman et al. (2015) reviewed the categories
of polyphenols in the DM treatment, including anthocyanin,
ellagitannin, luteolin, rosmarinic acids, catechin, resberatrol,
rutin, quercetin, diosimin, and myricetin (Solayman et al., 2015).
Different polyphenols have different action mechanisms.
It was reported that polyphenols from black soybean seed coat
improved hyperglycemia and insulin sensitivity via regulating
AMPK signal pathway both in vitro and in vivo, and anthocyanins
[cyanidin 3-glucoside (C3G)] and procyanidins (PCs) were
the main antidiabetic polyphenols, which could also enhanced
glucose uptake (Kurimoto et al., 2013). Polyphenols from
Vernonia amygdalinawere reported to possess antihyperglycemic
effects, most probably via increasing GLUT4 translocation and
inhibiting hepatic G6Pase (Ong et al., 2010). EGCG, a kind of
green tea polyphenol, could improve endothelial dysfunction
and ameliorate metabolic IR in skeletal muscle and liver. And
it was reported that EGCG could attenuate the death of β-cells
in the db/db mouse, reduce IR, and increase the glucose-
induced insulin scretion (Ortsäter et al., 2012). Therefore, the
polyphenols could be a promising therapy to treat T2DM, obesity,
and cardiovascular, in which there were reciprocal relationships
between IR and endothelial dysfunction (Keske et al., 2015).
Other Constituents
Besides polysaccharides and polyphenols, there are other
constituents from natural products related to antidiabetic effects.
Several reviews provided summaries of the natural constituents
TABLE 1 | Polysaccharides applied on the treatment of diabetes mellitus.
Class Origin Effect and mechanisms Reference
Plant Astragalus membranaceus Improving insulin sensitivity; decreasing myostatin expression; downregulating
ROS-ERK-NF-κB pathway
Liu et al., 2013
Liriope spicata Improving PI3K signal pathway; upregulating the protein expression of PPARγ;
improving glucose metabolism
Xiao et al., 2014
Lycium barbarum Delaying the absorption of glucose; reducing the postprandial blood glucose Tang et al., 2015
Ophiopogon japonucus Regulating InsR/IRS-1/PI3K/Akt/GSK-3/Glut-4 signal pathway Wang et al., 2012
Cucurbita moschata Decreasing the levels of TG, TC, and LDL, cholestrol; increasing the levels of
fecal fat, and HDL
Zhao et al., 2013
Panax ginseng Alleviating oxidative stress; stimulating increased insulin secretion Sun et al., 2014
Mushroom Ganoderma Lucidum Upregulating Bcl-2 and PDX-1; downregulating Bax, iNOS, and Casp-3 mRNA
expressions
Zheng et al., 2012
Ganoderma atrum Activating PI3K/Akt/Enos signal pathway Zhu et al., 2014
Grifola frondosa Increasing the metabolism of glucose; regulating Akt/GSK-3 signal pathway Ma et al., 2014
Seaweed Enteromorpha prolifera Regulating the mRNA level of InsR, GCK, APN, and GLUT-4 gene in liver and
adipose tissue
Lin et al., 2015
Bacterial Trametes gibbosa Decreasing the levels of LDL-C BG, TG, and TC; increasing the level of HDL-C Ma et al., 2013
Animal Misgurnus anguillicaudatus Elevating the insulin level; increasing PEPCK mRNA expression; reducing
glycogen contents
Zhou et al., 2015
TABLE 2 | Polyphenols applied on the treatment of diabetes mellitus.
Origin Effects and mechanisms Reference
Ecklonia cava Improving blood glucose regulation; regulating hepatic glucose metabolic; upregulating Akt protein Kim et al., 2016
Folium Mori Increasing the mRNA and protein expression of IRS-1 of PI3K-p85α and Glut-4IRS-1/PI3K/Glut-4 signal pathway Cai et al., 2016
Litchi chinensis Sonn. Improving glucose tolerance and insulin resistance; influencing lipid metabolism; increasing mRNA levels of Bax and NF-κB Man et al., 2016
Corchorus olitorius α-amylase and α-glucosidase inhibitory; high antioxidant capacity Oboh et al., 2012
Theobroma cacao L. Ameliorating insulin sensitivity, glucose uptake, and adiponectin secretion via regulating MAPK signal pathway Ali et al., 2014
Grape seed Regulating MFG-E8, IL-1β and NLRP3 Yin et al., 2015
Curcuma longa Inhibiting the activation of the SphK1-S1P signal pathway Huang et al., 2013
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for DM therapy, such as terpenoids, tannins, saponins, alkaloids,
and lignans (Tundis et al., 2010; Hung et al., 2012; Zhang and
Jiang, 2012).
Traditional herbal medicine has been used to treat DM for
decades. Recent studies of antidiabetic compounds from 2010
to 2016 were categorized here. According to structure-activity
relationship, these action mechanisms of natural products are
quite different from those of the currently antidiabetic drugs.
Natural products might be the promising sources to provide
multi-components with multi-targets and new therapy for DM.
Database of DM
Network pharmacology is a new strategy to find the bioactive
constituents as well as the molecular targets and the interactions.
Nowadays, there are more studies and knowledge of DM
from published literatures and the protein–protein interaction
(PPI) databases (Liechti et al., 2010). Several databases such
as T1Dbase, T2D-Db, T2DGADB, and T2D@ZJU have
integrated the existing information, which contained genetic
association studies, gene expression, related signal pathways,
and PPI.
T1Dbase was a public website and database related to the
molecular genetics and biology of T1DM. T1Dbase integrated
the data from assembled genome sequences, derived gene
and transcript models, publications linked to genes, T1DM
susceptibility regions, genetic linkage and related studies. It
provided integrated data and opportunities for researchers to
explore the complex pathogenesis of T1DM which was affected
by various factors (Hulbert et al., 2007).
T2D-Db collected 330 candidate genes from the Pubmed
literatures and provided their corresponding information on
almost all known molecular components involved in the
pathogenesis of T2DM. Information on candidate genes had
been established in this on line database, including SNPs (single
nucleotide polymorphism) in candidate genes or candidate
regions, GWA (genome wide association studies), pathways, PPI
and diseases associated risk factors or complications (Agrawal
et al., 2008).
T2DGADB collected 701 publications in T2DM genetic
associated research area. It aimed to provide specialized
information on the genetic risk factors involved in the
development of T2DM. And T2DGADB focused on information
related to each SNP association including the populations used,
odds ratio and other factors (Lim et al., 2010).
T2D@ZJU summarized three levels of heterogeneous
connections related to T2DM, which was searched from
pathway databases, PPI databases and literatures. It contained
1,078 T2DM related substances including proteins and its
complexes, drugs and the interactions. Compared with T2D-
Db and T2DGADB, which focused on the genes associated
with T2DM, T2D@ZJU organized the integrated information
through network. From the perspective of system biology, it
established a basis for the further research of T2DM, which was
contributed to the elucidation of the action mechanism and
related drug development. Furthermore, this database could also
promote the T2DM-related studies of network pharmacology
and multi-targets therapeutics (Yang et al., 2013).
The high availability of the DM databases plays a significant
role in integrating related complex data. They can be used to
predict the target network of the bioactive constituents. After
experimental validation of the molecular network, they can
provide a new perspective for researchers to better understand the
pathogenesis of DM and action mechanisms of associated drugs.
Action Mechanisms Related to T2DM
A large amount of studies have indicated that natural products
showed antidiabetic effects via a variety of mechanisms. The
present review summarizes and discusses the related antidiabetic
mechanisms.
α-Amylase and α-Glucosidase Inhibitory
It has been reported that the inhibition of α-amylase and
α-glucosidase could be an important concept for therapy
of T2DM. Dietary carbohydrates can be hydrolyzed into
oligosaccharide and then into monosaccharide including
glucose, which is produced by the main hydrolyzing enzymes
such as pancreatic α-amylase and intestinal α-glucosidase.
The α-amylase hydrolyzes α-1,4-glycocidic bonds and
produced smaller oligosaccharides and disaccharides, while
the α-glucosidase hydrolyzes disaccharides to monosaccharide
(Apostolidis and Lee, 2010). Therefore, it is an effective approach
to manage the blood glucose level via inhibiting the activities of
α-amylase and α-glucosidase (Striegel et al., 2015).
Targeting β Cell Dysfunction
The β cell dysfunction and IR are inherently complex with
their interrelation for triggering the pathogenesis of DM. It
results from inadequate glucose sensing to stimulate insulin
secretion. Cytokine-induced inflammation, oxidative stress, and
overconsumption of saturated fat and free fatty acids can cause
β cell dysfunction (Cerf, 2013). Therefore, preserving β cell
function with anti-inflammatory effect and antioxidant effect can
maintain glucose homeostasis (Nguyen et al., 2012; Hasnain et al.,
2016).
Targeting Signal Pathways
There are various sophisticated signal pathways related to DM
that can be therapeutically targeted. The present review provides
a summary of signal pathways related to DM (Figure 1),
including AMPK signal pathway (Kurimoto et al., 2013),
PI3K/Akt signal pathway (Li et al., 2015), mTOR signal
pathway (Siegel, 2008), JAK-STAT signal pathway (Gurzov
et al., 2016), ROS-ERK-NF-κB signal pathway (Liu et al.,
2013), Wnt signal pathway (Chiang et al., 2012), and IGF-
1 signal pathway (Siddle, 2011). By targeting these signal
pathways, the bioactive constituents can produce multiple effects
including glut translocation, glut trafficking, glycogen synthesis,
glycolysis, lipolysis, microtubules, gluconeogenesis, lipogenesis,
and autophagy.
Modulation of Gut Microbiota
The gut microbiota was hypothesized to play a critical role in
metabolic diseases, including T2DM (Xu et al., 2015). Ge-Gen-
Qin-Lian decoction (GQD) formula, consisted of four herbs:
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FIGURE 1 | Summary of signal pathways related to diabetes mellitus. Pathway diagram keys: Direct stimulatory modification; Direct inhibitory
modification; Translocation; Multistep stimulatory modification.
Puerariae Lobatae radix (Ge-Gen), Coptidis rhizoma (Huang-
Lian), Scutellariae radix (Huang-Qin), and Glycyrrhizae Radix
et Rhizoma Praeparata cum Melle (Gan-Cao), was treated
for “Xiaoke,” namely T2DM. GQD treatment conspicuously
modulated gut microbial metabolism by degradation of choline
into methylamines, together with a decrease in FBG and an
expansion of islets in STZ and high-fat-diet-induced diabetic
rats (Tian S. et al., 2013). In addition, GQD could modulate
the composition of the intestinal microbiota during T2DM
clinical treatment, especially enrich the quantity of beneficial
bacteria such as Faecalibacterium spp., and it was found that
structural alterations in the gut microbiota were associated
with the anti-diabetic effects of GQD (Xu et al., 2015). What’s
more, in the study of Wang et al. (2016), the quality and
quantity of Lactobacillus and Bacteroides genus were significantly
increased with the increasing concentration of POCS. The results
indicated that POCS could restore the intestinal microbiota
balance for the treatment of T2DM. Because most of the herbal
drugs were usually orally administrated, the modulation of
the herbal drugs on the intestine microbiota has been new
mechanistic understanding of the natural products in DM
treatment.
Compared with initial time-consuming laboratory
experiments, network pharmacology approaches for well-
known pathways with various natural products will be more
efficient for antidiabetic drug discovery. Based on combining
the network, chemical, pharmacological, biomedical and
computational results, we can achieve multi-components and
multi-targets therapy for DM.
APPLICATIONS OF NETWORK
PHARMACOLOGY FOR DM THERAPY
Network pharmacology, as a powerful tool to elucidate complex
relationships from a systematic and biological level, has been
more and more popular in recent years. It has been applied
to various complex chronic diseases, such as cardio-cerebral
ischemic diseases (Gu et al., 2013b), cancer (Azmi et al., 2010;
Zhang et al., 2012; Poornima et al., 2016), pancreatitis (Hong
et al., 2016), gout (Zhao et al., 2015), Alzheimer’s disease and DM
and other metabolic disease (Loscalzo, 2011). For DM therapy,
network pharmacology has been widely used in the mechanism
studies.
According to the study of Liu et al. (2007), a gene network
enrichment analysis (GNEA) was used to identify two sets of
genes, IS-HD and NR-HD gene sets, which was associated with
insulin signal and a network of nuclear receptors. They identified
a network of PPI between members from IS-HD and NR-HD
gene sets that might facilitate signal. By using GNEA, it was found
that insulin-signal process was obviously transcriptionally altered
in IR and T2DM. Their results also indicated that integrating
high-throughput microarray studies together with PPI networks
was an effective method to prove the existing biological processes
associated with a complex disorder (Liu et al., 2007).
In the study of Li et al. (2014), the network pharmacology
method was used to assist detecting the potential antidiabetic
ingredients from the GQD. They collected 287 available chemical
components, with 42 of them found in Ge-Gen, 57 of them found
in Huang-Qin, 22 of them found in Huang-Lian, and 166 of them
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found in Gan-Cao. In this study, network target analysis was
applied to elucidate the relationships between herbal ingredients
and bioactivities. And the network pharmacology method also
contributed to better understand the action mechanisms of
GQD formula. It was also found that 4-Hydroxymephenytoin, a
novel compound from Puerariae Lobatae radix (Ge-Gen), could
increase the insulin secretion and improve IR (Li et al., 2014). The
network pharmacology approach had been an effective strategy
for the modern research on herbal drugs on the DM treatment,
and the multi-active compounds could be identified and the
multi-targets action mechanisms could be elucidated.
As the second most consumed beverage in the world next to
water, Tea (Camellia sinensis L.) had been used as antidiabetic
candidate for a long time according to folk remedies (Chen
et al., 2007). Tea polyphenols (GTPs) was one of the main
components of tea, mainly including EGCG, EGC, ECG, and
EC. Different GTPs could act on different targets in the signal
network of complex diseases (diabetes, cancer, cardiovascular,
etc.), resulting in a synergistic effect, which was in accordance
with the theory of network pharmacology. Study of network
pharmacology approach on GTPs identified three pathways,
p53 signal pathway, neurotrophin signal pathway, and T2DM
pathway, which related to DM from all 147 pathways. And they
established a diabetes-related pathway by integrating these three
pathways (Zhang S. et al., 2014).
In order to find the potential inhibitors from TCM for
the T2DM-related targets, Tian S. et al. (2013) developed an
integrated approach that combined molecular docking and
pharmacophore mapping, and they established the compound-
target interaction network. A total of 2,479 non-duplicated
compounds from these 32 Chinese herbs of 52 classical TCM
formulas were found from two databases. The Bayesian classifiers
with satisfactory discrimination capabilities for 15 targets were
employed to screen the 2,479 compounds. The results showed
that molecular docking or pharmacophore mapping could give
satisfactory predictions for most targets. It was proved that some
herbal ingredients could directly interact with T2DM related
targets, while some ingredients relieved T2DM via antioxidant
effects or other supplementary pharmacological effects (Tian S.
et al., 2013).
Zhao H.L. et al. (2012) reported that male Zucker diabetic
fatty rats were treated by JCU, a kind of TCM, which contained
three herbs and berberine. The results showed that JCU
could improve hyperglycemia, ameliorate IR, normalize liver
enzyme and hepatocyte ballooning degeneration. On three levels
including miRNA level, protein level and mRNA level, the study
elucidated the action mechanisms of JCU, regulating the critical
cytokines on the related pathways including improving the
quality and quantity of cell survival, increasing glucose uptake,
and ameliorating insulin sensitivity (Zhao H.L. et al., 2012). It
in-depth validated that there was of great significance of multi-
components TCM to treat DM.
In the work of Gu et al. (2011), the combination of
molecular docking and network pharmacology analysis was
developed to illustrate the action mechanism of Tangminling
Pills for T2DM therapy. The drug–drug network and drug-target
network illustrated that more than 100 active compounds of 667
compounds in the formula would target 37 target proteins related
to T2DM. That is, they played important roles in the biological
network. As well as the critical ingredients in Tangminling
Pills were predicted and some of them had been reported in
literatures. In addition, several compounds including Rheidin A,
Sennoside C, Rheidin C, procyanidin C1, and Dihydrobaicalin
were of importance as the antidiabetic candidate due to its
pharmacological effects (Gu et al., 2011).
CONCLUSION AND PERSPECTIVES
Diabetes mellitus, a complicated metabolic disease, is a currently
health problem causing significant mobility and mortality
worldwide, which can cause various complications such as
kidneys dysfunction, eyes damage, and cardiovascular diseases.
Current antidiabetic drugs are still limited due to single-
compound, single-target, side-effects, drug tolerance and low
efficacy and they can’t cure DM completely. And it is significant
that the world populations are heterogeneous and genetic
polymorphisms in pharmacologically relevant genes varying
across geographical region (Suarez-Kurtz et al., 2014). As a novel
perspective, network pharmacology is becoming more and more
popular in drug discovery. Compared with the single target of
the current antidiabetic drugs, it is an promising approach which
can combat the complex problems (Tao et al., 2014). It may
also contribute to better explain the low clinical efficacy, side
effects and toxicity of the current clinical drugs. At the same
time, natural products have vast structural diversity and various
bioactivities, which can provide the opportunities to find different
lead compounds, different targets for DM. Hence, limited studies
result in an urgent need to develop novel network pharmacology
approaches to change current theories of drug discovery and
to improve our understanding of action mechanisms. Although
network pharmacology of natural products is still in its infancy,
the appropriate use of network pharmacology approaches may
initiate new directions, overcome the disadvantages of current
antidiabetic therapies as well as contribute new insights into the
discovery of novel antidiabetic drugs. Specific researches can be
done to better elucidate the usage of natural products, and explore
the possible action mechanisms.
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